A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Chen KT, Madison R, Moore J, Jin D, Fleischmann Z, Newberg J, Schrock A, Bhardwaj N, Lofgren KT, He J, Frampton G, Hegde P, Fabrizio D, Pishvaian MJ, Ebot E, Singhi A, Sokol E.
Chen KT, et al.
Oncologist. 2023 Aug 3;28(8):691-698. doi: 10.1093/oncolo/oyad178.
Oncologist. 2023.
PMID: 37354528
Free PMC article.